Global /China /Healthcare /Drug Manufacturers - General /300294

China Resources Boya Bio-pharmaceutical Group Co.,Ltd

300294

• SHE: 300294 • Delayed

17.48CNY -1.4%

2.58 USD

As of 21 June 2026, China Resources Boya Bio-pharmaceutical Group Co.,Ltd has a market cap of $1.32B USD, ranking #9169 globally and #2462 in China. It ranks #784 in the Healthcare sector, and #298 in the Drug Manufacturers - General industry.

Global Rank

9169

Country Rank

2462

Sector Rank

784

Industry Rank

298

Key Stats

Market Cap

$1.32BUSD

8.94B CNY

Enterprise Value

$906.32MUSD

6.14B CNY

Revenue (TTM)

$272.93MUSD

1.84B CNY

EBITDA (TTM)

$45.44MUSD

307.62M CNY

Net Income (TTM)

$508.34KUSD

3.44M CNY

EBITDA Margin

17%

Profit Margin

0.2%

PE Ratio

2601.2

Forward PE

24.3

PS Ratio

4.8

PB Ratio

1.2

EV/EBITDA

19.6

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Xiaoming Liang open_in_new

Employees

1,947

Founded

1993

Website

china-boya.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.4%	-5%	-6.4%	-24%	-29%	-22%	-34%	-54%	-49%

News

Markets

Exchange	Ticker	Price	Quotes
Shenzhen Stock Exchange (SHE / SZSE) MIC: XSHE PRIMARY	300294 华润博雅生物制药集团股份有限公司 Class A ISIN: CNE100001FF1 Shares Out.: Shares Outstanding: 504.249M¹ Shares Float: 329.465M² TV: TradingView: SZSE: 300294 SA: Stock Analysis: SHE: 300294 YF: Yahoo Finance: 300294.SZ GF: Google Finance: SHE: 300294 BA: Barron's: 300294 MS: Morningstar: XSHE: 300294	17.48 CNY	TV: TradingView: SZSE: 300294 SA: Stock Analysis: SHE: 300294 YF: Yahoo Finance: 300294.SZ GF: Google Finance: SHE: 300294 BA: Barron's: 300294 MS: Morningstar: XSHE: 300294

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About China Resources Boya Bio-pharmaceutical Group Co.,Ltd

China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound bone peptide, oxytocin, heparin sodium injection, posterior pituitary, and carboprost tromethamine injection. In addition, it engages in research, development, production, and sales of anti-infective, diabetes, and cardiovascular drugs. The company was formerly known as Boya Bio-pharmaceutical Group Co., Ltd. and changed its name to China Resources Boya Bio-pharmaceutical Group Co.,Ltd. The company was founded in 1993 and is based in Fuzhou, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$54.0B 364.89B CNY 4K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.78B 336.36B CNY 4K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.51B 223.48B HKD 2K%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.8B 147.32B HKD 1K%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.56B 111.89B CNY 1K%	-	China
Akeso, Inc. SHEK: 9926	$16.01B 125.46B HKD 1K%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 58K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 41K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 27K%	97.4	United States
Roche Holding AG SIX: RO	$318.3B 256.25B CHF 24K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$284.64B 215.59B GBP 21K%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 21K%	15.1	United States

chevron_leftBack